Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)
Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by GAP stage
Ryerson CJ et al.
Effects of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) by composite physiologic index (CPI)
Nambiar AM et al.
Effect of nintedanib on decline in forced vital capacity (FVC) in patients with progressive fibrosing interstitial lung diseases (ILDs) by time since diagnosis
Strek ME et al.
Effects of nintedanib in patients with progressive fibrosing interstitial lung diseases (ILDs) taking anti-acid therapy
Kreuter M et al.
Decline in forced vital capacity as a surrogate for mortality in patients with fibrosing interstitial lung diseases
Maher TM et al.
Lung function decline and hospitalization among patients with non-IPF fibrosing interstitial lung disease as observed in a large real-world electronic health record database
Singer D et al.
Incremental healthcare resource utilization and cost burden associated with non-IPF chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype
Singer D et al.
